111In- and 90Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial

Seminars in Nuclear Medicine

Volumn 32, Issue 2, 2002, Pages 148-155

  Virgolini, Irene ^a,b,c,d,e,f   Britton, Keith ^a,b,c,d,e   Buscombe, John ^a,b,c,d,e   Moncayo, Roy ^a,b,c,d,e   Paganelli, Giovanni ^a,b,c,d,e   Riva, Pietro ^a,b,c,d  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e BUFALINI HOSPITAL   (Italy)

^f GENERAL HOSPITAL LINZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ANGIOPEPTIN 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANGIOPEPTIN 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; ANGIOPEPTIN 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; DEPREOTIDE TC 99M; OCTREOTATE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; OCTREOTATE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GA 67; OCTREOTATE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; OCTREOTIDE; OCTREOTIDE[1 DEXTRO PHENYLALANINE 3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GA 67; OCTREOTIDE[1 DEXTRO PHENYLALANINE 3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; OCTREOTIDE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; P 829; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; CYCLOPEPTIDE; HETEROCYCLIC COMPOUND; INDIUM; INDIUM 111 DOTA LANREOTIDE; INDIUM 111-DOTA-LANREOTIDE; RADIOPHARMACEUTICAL AGENT; YTTRIUM; YTTRIUM 90 DOTA LANREOTIDE; YTTRIUM 90-DOTA-LANREOTIDE;

ARTICLE; BLOOD TOXICITY; BRAIN TUMOR; CARCINOID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; ISOTOPE LABELING; LIGAND BINDING; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PANCREAS CANCER; RADIOISOTOPE THERAPY; THYMOMA; THYROID CANCER; TREATMENT OUTCOME; CHEMISTRY; NEOPLASM; PHASE 2 CLINICAL TRIAL;

HETEROCYCLIC COMPOUNDS; HUMANS; INDIUM RADIOISOTOPES; NEOPLASMS; PEPTIDES, CYCLIC; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; YTTRIUM RADIOISOTOPES;

EID: 0036231005     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2002.31565     Document Type: Article

References (48)

1. Hypo-thalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
2. Somatostatin antisense oligodeoxynucleotide-mediated stimulation of lymphocyte proliferation in culture
3. Somatostatin analogues suppress the inflammatory reaction in vivo
4. Cloning and functional characterization of family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney
5. Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase
6. Cloning of a somatostatin receptor, SSTR3, coupled to adenylylcyclase
7. Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20
8. A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides
9. Cloning and characterization of a fourth human somatostatin receptor
10. Octreotide
11. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors
12. Localization of endocrine-related tumors with radioiodinated analogue of somatostatin
13. 123I-Tyr-3-]-octreotide
14. Indium-111-DOTA-lanreotide: A novel tumor diagnostic and therapeutic somatostatin analog
15. 3]octreotide; comparison with [In-111-DTPA-D-Phe-1]-octreotide in humans
16. Yttrium-90-labeled somatostatin-analogue for cancer treatment
17. Indium-111-DOTA-lanreotide: Biodistribution, safety and radiation absorbed dose tumor patients
18. 90Y-DOTA-lanreotide of a patient with metastaticgastrinoma
19. New trends in peptide receptor radioligands
20. 90Y-DOTA-lanreotide scintigraphy and therapy: Initial clinical results of "MAURITIUS"
21. 90Y-DOTA-lanreotide in the treatment of anaplastic or metastatic undifferentiated thyroid carcinoma
22. Use of radiolanreotide to treat somatostatin receptor positive tumors
23. Treatment of somatostatin receptor (SSTR) positive tumors with Y-90-DOTA-lenreotide: Preliminary studies
24. Tumor-targeted radionuclide therapy trial design driven by patient dosimetry
25. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs
26. 111In-DTPA-octreotide scintigraphy by means of pretreatment with cold octreotide in small cell lung cancer
27. Solling: Studies on renal tubular protein reabsorption: Partial and near complete inhibition by certain amino acids
28. 90Y-DOTA-octreotide therapy
29. Inhibition of renal uptake of Indium-111-DTPA-octreotide in vivo
30. Aminoacid infusion blocks renal tubular uptake of an indium-labeled somatostatin analog
31. 1-octreotide in vivo
32. Somatostatin receptor: Scintigraphy and radionuclide therapy
33. 111In-DTPA-D-Phel]-octreotide in patients with neuroendocrine tumors-evaluation and toxic effects
34. 111In pentreotide. State of the art and perspectives
35. Targeted treatment of disseminated NETs with radiopeptides
36. Internalisation of radiolabeled DTPA-octreotide and DOTA-tyr3-octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy
37. Yttrium-90 DOTATOC: First clinical results
38. 3-octreotide
39. OctreoTher: Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy
40. 90Y-DOTATOC) of neuroendocrine tumor tissue: First phase II study
41. 3-octreotide
42. 90Y-SMT487: OCTREOTHER®): A phase I study
43. 3) octreotide is dependent on the peptide amount
44. 111In-labeled somatosta-tin analogs is dependent on tumor size
45. 3-octreotide: Implications for internal radiotherapy with Y-90-DOTATOC
46. 177Lu, is most promising for radionuclide therapy of somatostatin receptor-positive tumors
47. 111In-DTPA-octreotide in patients
48. Graves' disease